|
Acute tonsillopharyngitis
|
A Timen et al., 2015 [60]
|
EPs 7630 (n = 40)
|
7.4 ± 1.2, 6–9
|
26 (65.0%)
|
14 (35.0%)
|
|
Placebo (n = 38)
|
7.7 ± 1.2, 6–9
|
18 (47.4%)
|
20 (52.6%)
|
|
B Berezhnoi et al., 2016 [55]
|
EPs 7630 (n = 60)
|
7.6 ± 1.1, 6–9
|
29 (48.3%)
|
31 (51.7%)
|
|
Placebo (n = 64)
|
7.4 ± 1.2, 6–9
|
28 (43.8%)
|
36 (56.3%)
|
|
C Bereznoy et al., 2003 [56]
|
EPs 7630 (n = 73)
|
7.6 ± 1.3, 6–9
|
40 (54.8%)
|
33 (45.2%)
|
|
Placebo (n = 70)
|
7.5 ± 1.1, 6–9
|
30 (42.9%)
|
40 (57.1%)
|
|
Acute bronchitis
|
D§ Kamin et al., 2010a [58]
|
EPs 7630 (n = 25)
|
7.8 ± 1.3, 6–10
|
14 (56.0%)
|
11 (44.0%)
|
|
Placebo (n = 24)
|
7.9 ± 1.7, 6–10
|
11 (45.8%)
|
13 (54.2%)
|
|
E§ Kamin et al., 2010b [59]
|
EPs 7630 (n = 32)
|
8.2 ± 1.3, 6–10
|
16 (50.0%)
|
16 (50.0%)
|
|
Placebo (n = 31)
|
7.9 ± 1.5, 6–10
|
15 (48.4%)
|
16 (51.6%)
|
|
F§ Kamin et al., 2012 [57]
|
EPs 7630& (n = 35)
|
7.7 ± 1.3, 6–10
|
21 (60.0%)
|
14 (40.0%)
|
|
Placebo (n = 31)
|
7.4 ± 1.3, 6–10
|
16 (51.6%)
|
15 (48.4%)
|
|
Pooled data (acute tonsillopharyngitis + acute bronchitis)
|
EPs 7630 (n = 265)
|
7.7 ± 1.2, 6–10
|
146 (55.1%)
|
119 (44.9%)
|
|
Placebo (n = 258)
|
7.6 ± 1.3, 6–10
|
118 (45.7%)
|
140 (54.3%)
|
